Wei Xu

Prof. Wei Xu

Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2020 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
YHYuan Huang
Yuan Huang
CYChan Yang
Chan Yang
XXXin-Feng Xu
Xin-Feng Xu
WXWei Xu
Wei Xu
Shuwen LiuShuwen Liu
Shuwen Liu

6 October 2020 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
CYChan Yang
Chan Yang
XPXiaoyan Pan
Xiaoyan Pan
XXXinfeng Xu
Xinfeng Xu
CCChen Cheng
Chen Cheng
YHYuan Huang
Yuan Huang
Shuwen LiuShuwen Liu
Shuwen Liu

1 October 2021 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
YXYunxia Xu
Yunxia Xu
KCKe Chen
Ke Chen
JPJuanli Pan
Juanli Pan
YLYingshou Lei
Yingshou Lei
DZDanting Zhang
Danting Zhang
WXWei Xu
Wei Xu

22 February 2021 in Advanced Therapeutics
Verified
Journal Article
Closed access
PDF file
CYChan Yang
Chan Yang
XPXiaoyan Pan
Xiaoyan Pan
YHYuan Huang
Yuan Huang
CCChen Cheng
Chen Cheng
XXXinfeng Xu
Xinfeng Xu
WXWei Xu
Wei Xu

6 September 2023 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
JLJiaxuan Li
Jiaxuan Li
YLYang Li
Yang Li
YLYanmei Li
Yanmei Li
YMYi Ma
Yi Ma
WXWei Xu
Wei Xu
JWJufang Wang
Jufang Wang

9 February 2023 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
YMYan-Hong Ma
Yan-Hong Ma
XHXu Hong
Xu Hong
FWFang Wu
Fang Wu
XXXin-Feng Xu
Xin-Feng Xu
RLRui Li
Rui Li
WXWei Xu
Wei Xu
Ebola virus (EBOV) causes hemorrhagic fever in humans with high morbidity and fatality. Although over 45 years have passed since the first EBOV outbreak, small molecule drugs are not yet available. Ebola viral protein VP30 is a unique RNA synthesis cofactor, and the VP30/NP interaction plays a critical role in initiating the transcription and propagation of EBOV. Here, we designed a high-throughput screening technique based on a competitive binding assay to bind VP30 between an NP-derived peptide and a chemical compound. By screening a library of 8004 compounds, we obtained two lead compounds, Embelin and Kobe2602. The binding of these compounds to the VP30-NP interface was validated by dose-dependent competitive binding assay, surface plasmon resonance, and thermal shift assay. Moreover, the compounds were confirmed to inhibit the transcription and replication of the Ebola genome by a minigenome assay. Similar results were obtained for their two respective analogs (8-gingerol and Kobe0065). Interestingly, these two structurally different molecules exhibit synergistic binding to the VP30/NP interface. The antiviral efficacy (EC50) increased from 1 μM by Kobe0065 alone to 351 nM when Kobe0065 and Embelin were combined in a 4:1 ratio. The synergistic anti-EBOV effect provides a strong incentive for further developing these lead compounds in future studies.